Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 3 , Pages 206-212 , March 2011

Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction

Received 4 March 2009 ,Revised 29 July 2009 ,Accepted 7 September 2009.

References 

  1. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–3072
  2. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual component of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol. 2007;6:13
  3. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27–38
  4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  5. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural hystory of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–794
  6. ATP III . Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2893–2898
  7. Expert Committee on the diagnosis and classification of diabetes mellitus . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–3167
  8. Utzschneider KM, Prigeon RL, Tong J, Gerchman F, Carr DB, Zraika S, et al. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia. 2007;50:2516–2525
  9. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sept;22(9):1462–1470
  10. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E871–E883Epub 2006 Nov 14
  11. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and b-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993 Nov;42:1663–1672
  12. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity. 2008 Aug;16:1901–1906
  13. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008 Mar;40(3):194–199
  14. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007 Mar;30(3):677
  15. Jensen CC, Cnop M, Hull RL, Fujiomoto WY, Kahn SE. American Diabetes Association GENNID Study Group: beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 2002 Jul;51(7):2170–2178
  16. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997 Sep 1;100(5):1166–1173
  17. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in african–american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes. 2002 Oct;51(10):3014–3019
  18. Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J. NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes. 2003 Oct;52(10):2513–2518
  19. Alemzadeh R, Tushaus KM. Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide. Endocrinology. 2004;145(12):5476–5484
  20. Shanik MH, Xu Y, Shrha J, Daukner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care. 2008 Feb;31(Suppl. 2):S262–S268
  21. Aston-Mourney K, Proiett J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia. 2008 Feb;51:540–545
  22. Hanley AJG, Wagenknecht LE, D'Agostino RB, Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 2003;52:2740–2743
  23. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, Mari A, Diamant M. Lack of association of liver fat with model parameters of beta-cell function in men with impaired glucose tolerance and type 2 diabetes. Eur J Endocrinol. 2008 Sept;159(3):251–257

PII: S0939-4753(09)00216-6

doi: 10.1016/j.numecd.2009.09.003

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 3 , Pages 206-212 , March 2011

Article Tools

* Image Usage & Resolution